These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 31170515)

  • 1. Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.
    Donovan JL; Opmeer B; Young GJ; Mills N; Martin RM; Lane JA; Metcalfe C; Peters TJ; Davis M; Turner EL; Walsh E; Neal DE; Hamdy FC;
    J Clin Epidemiol; 2019 Sep; 113():200-213. PubMed ID: 31170515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences.
    Mills N; Blazeby JM; Hamdy FC; Neal DE; Campbell B; Wilson C; Paramasivan S; Donovan JL
    Trials; 2014 Aug; 15():323. PubMed ID: 25115160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial.
    Donovan JL; Young GJ; Walsh EI; Metcalfe C; Lane JA; Martin RM; Tazewell MK; Davis M; Peters TJ; Turner EL; Mills N; Khazragui H; Khera TK; Neal DE; Hamdy FC;
    J Clin Epidemiol; 2018 Apr; 96():35-46. PubMed ID: 29288137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring treatment preferences facilitated recruitment to randomized controlled trials.
    Mills N; Donovan JL; Wade J; Hamdy FC; Neal DE; Lane JA
    J Clin Epidemiol; 2011 Oct; 64(10):1127-36. PubMed ID: 21477994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
    Mills N; Donovan JL; Smith M; Jacoby A; Neal DE; Hamdy FC
    Control Clin Trials; 2003 Jun; 24(3):272-82. PubMed ID: 12757993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer.
    Elliott D; Hamdy FC; Leslie TA; Rosario D; Dudderidge T; Hindley R; Emberton M; Brewster S; Sooriakumaran P; Catto JWF; Emara A; Ahmed H; Whybrow P; le Conte S; Donovan JL
    BJU Int; 2018 Dec; 122(6):970-977. PubMed ID: 29888845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult.
    Donovan J; Mills N; Smith M; Brindle L; Jacoby A; Peters T; Frankel S; Neal D; Hamdy F
    BMJ; 2002 Oct; 325(7367):766-70. PubMed ID: 12364308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
    Hissink Muller PCE; Yildiz B; Allaart CF; Brinkman DMC; van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Ten Cate R; de Vries MC
    BMC Med Ethics; 2018 Dec; 19(1):96. PubMed ID: 30572875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.
    van Tol-Geerdink JJ; Willem Leer J; Weijerman PC; van Oort IM; Vergunst H; van Lin EN; Alfred Witjes J; Stalmeier PF
    BJU Int; 2013 Apr; 111(4):564-73. PubMed ID: 22882966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Prostate Cancer Intervention Versus Observation Trial: VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):184-90. PubMed ID: 23271771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
    Donovan JL; Peters TJ; Noble S; Powell P; Gillatt D; Oliver SE; Lane JA; Neal DE; Hamdy FC;
    J Clin Epidemiol; 2003 Jul; 56(7):605-9. PubMed ID: 12921927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
    Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evidence review of active surveillance in men with localized prostate cancer.
    Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
    Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating Patient Preference into Treatment Decisions for Men with Prostate Cancer at the Point of Care.
    Johnson DC; Mueller DE; Deal AM; Dunn MW; Smith AB; Woods ME; Wallen EM; Pruthi RS; Nielsen ME
    J Urol; 2016 Dec; 196(6):1640-1644. PubMed ID: 27346032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating preferences for treatments in patients with localized prostate cancer.
    Ávila M; Becerra V; Guedea F; Suárez JF; Fernandez P; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Cunillera O; Pardo Y; Cots F; Ferrer M;
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):277-87. PubMed ID: 25491504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a complex intervention improved randomization and informed consent in a randomized controlled trial.
    Donovan JL; Lane JA; Peters TJ; Brindle L; Salter E; Gillatt D; Powell P; Bollina P; Neal DE; Hamdy FC;
    J Clin Epidemiol; 2009 Jan; 62(1):29-36. PubMed ID: 18619811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring decisional control preferences in men newly diagnosed with prostate cancer.
    Henrikson NB; Davison BJ; Berry DL
    J Psychosoc Oncol; 2011; 29(6):606-18. PubMed ID: 22035534
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.